Grifols, ES0171996087

Wall Street Zen downgrades Grifols stock from Buy to Hold

Published on 10/13/2026 at 10:08 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Wall Street Zen cut Grifols from Buy to Hold on October 10, 2026. Grifols stock was EUR 9.96 at Lang & Schwarz on October 13, 2026.

Key points in brief

Wall Street Zen downgraded Grifols from Buy to Hold on October 10, 2026.
First-half 2026 revenue reached EUR 3.574 billion, up 2.60 percent at constant currency.
Net profit rose 28.70 percent to EUR 227.0 million in the first half of 2026.
Grifols stock was EUR 9.96 at Lang & Schwarz on October 13, 2026.
The next earnings date is listed as November 10, 2026.

Schwarzweiß-Reportagefoto einer Plasma-Spendeklinik mit Personal und Spendern — Dokumentarische Schwarzweiß-Reportage porträtiert Grifols S.A. ES0171996087 im Alltag einer Plasma-Spendeklinik mit medizinischem Personal, Illustration mit AI erstellt.

Grifols (ISIN ES0171996087) stock was EUR 9.96 at Lang & Schwarz on October 13, 2026 at 10:03 a.m. CEST. Wall Street Zen downgraded Grifols from Buy to Hold in a research note issued on October 10, 2026, according to MarketBeat.

Analyst caution meets stronger profit

The downgrade contrasts with Grifols' first-half operating progress. The company reported EUR 3.574 billion in revenue for the first half of 2026, up 2.60 percent at constant currency, while net profit rose 28.70 percent to EUR 227.0 million, according to Quartr on October 1, 2026.

The earnings mix also matters. Adjusted EBITDA reached EUR 854.0 million in the first half of 2026, up 2.40 percent at constant currency, with an adjusted EBITDA margin of 23.90 percent, according to Yahoo Finance.

What does the downgrade weigh against?

The central counterweight is execution. Management kept full-year 2026 guidance in place and reported EUR 91.0 million of free cash flow before mergers and acquisitions in the first half, EUR 103.0 million higher than a year earlier, according to Quartr.

Grifols also confirmed full-year free cash flow guidance of EUR 500.0 million to EUR 575.0 million before mergers and acquisitions. The company said the Biopharma division grew 5.40 percent at constant currency in the first half, while immunoglobulin sales increased 12.90 percent, making the segment the main operational support for the outlook.

Three dated results milestones

On May 7, 2026, Grifols reported first-quarter revenue of EUR 1.7 billion and net profit of EUR 73.0 million in its investor update, according to Grifols. On July 28, 2026, first-half revenue reached EUR 3.574 billion and net profit reached EUR 227.0 million. On October 10, 2026, Wall Street Zen moved its rating from Buy to Hold, as reported by MarketBeat.

Next reporting date

The next Grifols earnings report is listed for November 10, 2026, according to TradingView.

Stock stays below its yearly high

Grifols stock was EUR 9.96 at Lang & Schwarz on October 13, 2026 at 10:03 a.m. CEST. The quoted 52-week range was EUR 8.43 to EUR 12.21, while market capitalization stood at EUR 6.8 billion on October 13, 2026. The comparison leaves the market weighing improved first-half profitability against the execution demands behind the 2026 outlook. The further course of trading is shown by the continuously updated real-time quote of Grifols stock.